Introduction
============

Colorectal cancer (CRC) is the third most prevalent type of cancer in males and the second most prevalent in females, with an estimated 693,900 mortalities occurring in 2012, worldwide.[@b1-ott-10-1017] According to a recent report, the CRC incidence and mortality rates in China have been increasing in the past few years due to late tumor stages at the time of presentation and rapid progression.[@b2-ott-10-1017] Occurrence and progression of cancer are multistep processes that involve epithelial cell proliferation, apoptosis, and differentiation.[@b3-ott-10-1017],[@b4-ott-10-1017] In recent years, substantial progress has been made in the diagnosis and treatment of CRC; however, mortality caused by CRC remains high. Therefore, various studies have been conducted to investigate the molecular abnormalities associated with CRC, in order to further elucidate its molecular pathogenesis.[@b5-ott-10-1017]--[@b7-ott-10-1017]

Long non-coding RNAs (lncRNAs), which were first described by Brockdorff et al in 1992, are defined as non-protein-coding RNA molecules having \>200 nucleotides in length, which may be located in the cell nucleus or cytoplasm.[@b8-ott-10-1017] In recent years, an increasing number of lncRNAs have been reported to play crucial roles in a wide variety of biological processes and to be involved in almost all aspects of gene regulation, including genomic imprinting, chromatin modification, and posttranscriptional processing.[@b9-ott-10-1017]--[@b12-ott-10-1017] Furthermore, numerous studies have indicated that certain lncRNAs are critical for various cellular processes, such as apoptosis, cell cycle progression, and cell invasion and proliferation. It has been demonstrated that the dysregulation of lncRNAs, such as HOX transcript antisense RNA (HOTAIR), Dreh, lncRNA-ATB, LINC00473, and prostate cancer-associated transcript 5, may have a negative effect on the prognosis of patients with breast cancer, hepatocellular carcinoma, non-small cell lung cancer, gastric cancer, and prostate cancer by promoting cell proliferation and invasion.[@b13-ott-10-1017]--[@b17-ott-10-1017] Likewise, the dysregulation of MYCLo-2, CCAT1, and CCAT3\~8 may have a significant effect in CRC by regulating MYC, which is known to regulate lncRNAs and has been implicated in cancer cell proliferation and tumorigenesis.[@b18-ott-10-1017],[@b19-ott-10-1017] Therefore, these lncRNAs have been the focus of numerous studies worldwide.

The present study focused on the lncRNA upregulated in bladder cancer 1 (linc-UBC1), which has a transcript length of 2,616 bp and is located on chromosome 1q32.1. It has been confirmed that linc-UBC1 physically combines with polycomb repressive complex 2 (PRC2), of which the core components are SUZ12 and enhancer of zeste 2 (EZH2). Hence, linc-UBC1 may mediate cell growth, proliferation, and invasion and has been shown to be upregulated in bladder and gastric cancer.[@b20-ott-10-1017],[@b21-ott-10-1017] It is estimated that a substantial proportion (24%) of lncRNAs expressed in a cell, including some that are strongly associated with CRC, are physically associated with PRC2.[@b22-ott-10-1017],[@b23-ott-10-1017] The dysregulation of linc-UBC1 has been recognized to be a potential biological signature of CRC; however, its specific expression pattern with regard to CRC remains to be elucidated.

This study aimed to explore the gene expression pattern of linc-UBC1 in CRC cell lines and in tissue samples from CRC patients and to analyze the potential associations between clinicopathological features and linc-UBC1 levels. Furthermore, the effects of linc-UBC1 expression on the biological properties of CRC cells were examined using RNA interference experiments.

Materials and methods
=====================

Ethics statement
----------------

The present study was authorized by the Research Ethics Review Board of Guangdong No 2 Provincial People's Hospital (Guangzhou, China), and each participant provided written informed consent.

Tissue specimens
----------------

Fresh clinical CRC specimens and adjacent normal tissues (≥5 cm from tumor tissues) were obtained from 96 patients who underwent surgical treatment for CRC between January 2010 and June 2011 at Guangdong No 2 Provincial People's Hospital. All specimens were harvested from patients who had not received chemotherapy or radiotherapy prior to surgery. All tissues were immediately placed in liquid nitrogen in a freezing tube following surgery and were stored at -80°C until the extraction of total RNA was performed. All CRC and adjacent non-tumor mucosa tissues were confirmed by experienced pathologists. Clinicopathological information and follow-up data of the 96 patients were also collected.

Cell culture conditions
-----------------------

Four CRC cell lines (SW480, HCT116, HT29, and SW620) and an intestinal epithelial cell line (NCM460) were donated by Dr Jinjun Rao (College of Pharmacy, Southern Medical University, Guangzhou, China). The cancer cell lines were incubated in Gibco RPMI-1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) while NCM460 cells were cultured in HyClone Dulbecco's Modified Eagle's Medium (GE Healthcare Life Sciences, Logan, UT, USA); both types of media were supplemented with 10% HyClone fetal bovine serum (FBS; GE Healthcare Life Sciences). Cells were cultured at 37°C in a humidified environment containing 5% CO~2~.

RNA extraction and reverse transcription (RT)-quantitative polymerase chain reaction (qPCR) analysis
----------------------------------------------------------------------------------------------------

Total RNA was extracted from cultured cells or tissue specimens using RNAiso Plus (catalog no 9108Q; Takara Biotechnology Co., Ltd., Dalian, China) following the product manual. RNA was quantified using NanoDrop 2000 (Thermo Fisher Scientific) and stored at -80°C until use. For each sample, total RNA (500 ng) from all cells and tissues was reverse transcribed to cDNA using the PrimeScript RT™ Master Mix (catalog no RR036A; Takara Biotechnology Co., Ltd.) following the manufacturer's protocol on a gradient PCR machine (Eppendorf China Ltd., Shanghai, China). Following the RT reaction, qPCR was employed to explore the relative expression patterns of linc-UBC1 with SYBR^®^ Premix Ex Taq™ II (catalog no RR820A; Takara Biotechnology Co., Ltd.) in an ABI 7500 System (Applied Biosystems; Thermo Fisher Scientific) according to the product manual. The primers used were as follows: linc-UBC1 forward, 5′-CGCTCTGCTCCAGTTATGTA-3′; linc-UBC1 reverse, 5′-GAAGGCAAGGAATGAGGTGG-3′; β-actin forward, 5′-CCTGGCACCCAGCACAAT-3′; and β-actin reverse, 5′-GGGCCGGACTCGTCATAC-3′. qPCR consisted of an initial denaturation step at 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. The specificity of the PCR amplification was ascertained by the melting curve, which only had a single peak. The relative gene expression levels of linc-UBC1 were calculated using the comparative quantification cycle (Cq) method (2^−ΔΔCq^) using β-actin as the endogenous control.

RNA interference
----------------

The functional relevance of linc-UBC1 in CRC cell lines was investigated using linc-UBC1-specific small interfering RNAs (siRNAs). The nucleotide sequences of the siRNAs were as follows: si-linc-UBC1-1, 5′-GGUUUCUGCCCUCAUCCUU-3′; si-linc-UBC1-2, 5′-GCUUCUAGUCCUCUCCUUA-3′; si-linc-UBC1-3, 5′-GCUGGAACCCAUUUACUAA-3′; and negative control (si-NC), 5′-CGUGGGUGGAUGCAUGGAUTT-3′. siRNAs were chemically synthesized by GenePharma Co. (Shanghai, China) and transfected into SW620 cells using Invitrogen Lipofectamine™ 2000 transfection reagent (catalog no 11668-019; Thermo Fisher Scientific) according to the manufacturer's protocol. The silencing efficiency was evaluated at 48 h after transfection using RT-qPCR. The siRNA that demonstrated the most significant silencing capacity was further utilized for functional investigations in the cell line.

Cell proliferation assay
------------------------

Cell viability was assessed using a cell counting kit-8 (CCK-8) assay. Each well of a 96-well plate contained \~5,000 transfected cells. Following incubation for 0, 24, 48, 72, or 96 h, 10 µL CCK-8 solution was added to each well of the 96-well plate and incubated for 2 h in an incubator. The absorbance value was determined at 450 nm using a multimode microplate reader (Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany).

Flow cytometry analysis of cell cycle and apoptosis
---------------------------------------------------

At 48 h after transfection, transfected SW620 cells were harvested by trypsinization and resuspended in cold phosphate-buffered saline for analysis. The rate of apoptosis in among the cells was detected by flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA) using an Annexin V-fluorescein isothiocyanate and propidium iodide (PI) apoptosis detection kit (BD Biosciences) according to the manufacturer's protocol. Cells were distinguished into early apoptosis, late apoptosis, dead, and viable cell groups.

For the analysis of cell cycle, the resuspended cells were fixed and stained with PI using a Cycletest™ Plus DNA Reagent kit (BD Biosciences) according to the manufacturer's manual, and were detected by flow cytometry. The percentages of cells in G0--G1, S, and G2--M phases were ascertained using software (Flow Jo, 7.6.2; FLOWJO, LLC, Ashland, OR, USA).

Western blot
------------

At 48 h after transfection, transfected SW620 cellular protein was extracted by a lysis buffer and quantified by a bicinchonininc acid kit (Beyotime, Shanghai, China). All the cellular protein lysates within this study were separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride membrane. Then, the membrane was incubated with specific primary antihuman antibodies followed by their respective appropriate secondary antibodies. The bands were visualized by electrochemiluminescence automatic chemiluminescence imaging analysis system (Tanon, Shanghai, China). A GAPDH antibody was used as a control, and the anti-Bcl-2, cleaved caspase-3 and cleaved caspase-9 (all 1:1,000) antibodies were purchased from Cell Signaling Technology, Inc. USA.

Cell migration and invasion assays
----------------------------------

SW620 cells transfected with si-linc-UBC1 or si-NC were harvested after 48 h. The cells were resuspended in serum-free medium and diluted to 3×10^5^ cells/mL, and \~100 µL of cell suspension was plated into the upper chambers of Transwell inserts (8.0-µm pore size; Costar; Corning Incorporated, Corning, NY, USA) for migration (without Matrigel) or invasion (with Matrigel) assays. The inserts were placed in 24-well plates containing 600 µL media with 10% FBS as a chemoattractant. After incubation for 24 h for migration and 48 h for invasion, cells were fixed with 4% triformol for 20 min and stained with 1% crystal violet. From five random fields, cell numbers were calculated and imaged under a microscope.

Statistical methods
-------------------

All statistical analyses were performed using SPSS version 20.0 (IBM SPSS, Armonk, NY, USA). Continuous variables were analyzed by the Student's *t*-test or one-way analysis of variance; normally distributed data were analyzed by Mann--Whitney *U*-test, and a Kruskal--Wallis test was used for data belonging to a non-normal distribution. Categorical variables were analyzed by the *χ*^2^ test. The overall survival rates were calculated by the Kaplan--Meier method, with the log-rank test applied for the comparison of differences. Hazard ratios were evaluated by univariate and multivariate Cox regression model. *P*\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Expression of linc-UBC1 is upregulated in CRC cells and tissues
---------------------------------------------------------------

The linc-UBC1 expression in 96 paired CRC tissues and matched non-tumor mucosa was assessed by RT-qPCR and the expression levels were normalized to β-actin. Significantly, the expression of linc-UBC1 was increased in CRC tissues compared with the paired adjacent normal tissues (*P*\<0.001, [Figure 1A](#f1-ott-10-1017){ref-type="fig"}). In addition, the expression of linc-UBC1 in CRC cells was compared with intestinal epithelial cells, revealing that the expression levels of linc-UBC1 were upregulated in the majority of CRC cell lines (SW620, HCT116, and HT29) (*P*\<0.01, [Figure 2A](#f2-ott-10-1017){ref-type="fig"}). The SW620 cell line exhibited the highest expression level. However, no significant difference in expression was identified between SW480 and NCM460 cells.

Overexpression of linc-UBC1 is associated with advanced TNM stages, large tumor size, greater tumor depth, lymph node metastasis, and poor prognosis of CRC
-----------------------------------------------------------------------------------------------------------------------------------------------------------

To analyze the associations of linc-UBC1 expression with clinicopathological variables, patients were classified into a low linc-UBC1 expression group (n=48) and a high linc-UBC1 expression group (n=48), using the median expression level of linc-UBC1 in CRC tissues as a cutoff. Notably, high expression of linc-UBC1 was significantly associated with advanced TNM stages, large tumor size, greater tumor depth, and the presence of lymph node metastasis (*P*\<0.05, [Table 1](#t1-ott-10-1017){ref-type="table"}). However, no significant associations were identified between linc-UBC1 expression and other clinicopathological features, including patient gender, age, tumor location, differentiation status, and distant metastasis.

Kaplan--Meier survival analysis was used to determine the value of linc-UBC1 in the prognosis of CRC patients. Among the 96 CRC cases, the high linc-UBC1 expression group was obviously associated with shorter overall survival time (*P*=0.002, [Figure 1B](#f1-ott-10-1017){ref-type="fig"}). Furthermore, multivariate analysis confirmed that high linc-UBC1 expression was a significant independent prognostic factor for overall survival in CRC patients (*P*=0.029, [Table 2](#t2-ott-10-1017){ref-type="table"}). In addition, TNM stage and distant metastasis were also shown to be independent prognostic factors, after controlling for other clinicopathological factors (*P*\<0.05, [Table 2](#t2-ott-10-1017){ref-type="table"}).

Manipulation of linc-UBC1 levels in CRC cells
---------------------------------------------

The sizable increase in linc-UBC1 expression in CRC samples and cells prompted exploration of the possible biological significance of linc-UBC1 in tumorigenesis. Based on their relatively higher expression of linc-UBC1, SW620 cells were transfected with si-NC or si-linc-UBC1 designed to knockdown linc-UBC1. Following transfection for 48 h, linc-UBC1 was effectively inhibited in SW620 cells (*P*\<0.001, [Figure 2B](#f2-ott-10-1017){ref-type="fig"}).

linc-UBC1 promotes proliferation of CRC cells
---------------------------------------------

After transfection, CCK-8 proliferation assays were conducted. The results revealed that proliferation of SW620 cells transfected with si-linc-UBC1-1 and si-linc-UBC1-2 was significantly inhibited compared with the si-NC-transfected SW620 cells (*P*\<0.05, [Figure 2C](#f2-ott-10-1017){ref-type="fig"}). Subsequently, flow cytometry was used to evaluate if the reduced proliferation of cells with low linc-UBC1 expression may be caused by cell cycle arrest or cell apoptosis. The results of the cell cycle analysis showed that the G2/M-phase fraction was increased from 8.14%±0.27% in si-NC-transfected cells to 22.87%±0.73% in si-linc-UBC1-1-transfected and 22.69%±1.23% in si-linc-UBC1-2-transfected cells; this indicated G2/M cell cycle arrest following linc-UBC1 knockdown (*P*\<0.01, [Figure 3B and C](#f3-ott-10-1017){ref-type="fig"}). Furthermore, the downregulation of linc-UBC1 induced a significant increase in the rate (14.23%±0.89% in si-NC-transfected cells to 27.21%±1.06% in si-linc-UBC1-1-transfected and 24.87%±0.93% in si-linc-UBC1-2-transfected cells) of apoptosis in SW620 cells (*P*\<0.001, [Figure 3A and D](#f3-ott-10-1017){ref-type="fig"}). Also, when transfected with si-linc-UBC1, cleaved caspase-3 and cleaved caspase-9 were significantly increased, whereas Bcl-2 was decreased compared with si-NC-transfected SW620 cells (*P*\<0.05, [Figure 4](#f4-ott-10-1017){ref-type="fig"}). These findings indicate that linc-UBC1 inhibits CRC cell apoptosis at least partly through the activation of specific caspase cleavage cascades.

linc-UBC1 promotes migration and invasion of CRC cells
------------------------------------------------------

Subsequently, to assess the effects of linc-UBC1 expression on CRC cell migration, a Transwell migration assay was performed using SW620 cells. As shown in the figures, fewer si-linc-UBC1-transfected SW620 cells migrated through the 8-µm pores of the Transwell chambers when compared to the cells transfected with si-NC. Furthermore, similar results were obtained in the invasion assay in which Transwell chambers were pre-coated with Matrigel (*P*\<0.01, [Figure 5](#f5-ott-10-1017){ref-type="fig"}). According to the results of this study, it is concluded that the migration and invasion capabilities of CRC cells were significantly inhibited following the knockdown of linc-UBC1.

Discussion
==========

Previous studies have demonstrated that abnormal lncRNA expression may be a crucial contributor to tumorigenesis.[@b13-ott-10-1017]--[@b19-ott-10-1017] The biological processes that may be affected by lncRNA expression include chromosome imprinting, cytoplasmic transport, X-chromosome inactivation, and cell differentiation.[@b24-ott-10-1017],[@b25-ott-10-1017] These findings indicate that lncRNAs may act as independent biomarkers for prognosis and diagnosis. linc-UBC1, which physically associates with PRC2, may play an important role in the occurrence and development of tumors, and has been found to be upregulated in bladder and gastric cancers.[@b20-ott-10-1017],[@b21-ott-10-1017] However, the exact function of linc-UBC1 in CRC remains unknown.

The results of the present study revealed that linc-UBC1 was significantly overexpressed in CRC tissues compared with that in corresponding noncancerous tissue. Furthermore, the expression of linc-UBC1 in the majority of the CRC cell lines was higher than that in NCM460 normal intestinal epithelial cells. Statistical analysis revealed that high linc-UBC1 expression level was associated with various clinicopathological features of CRC, including large tumor size, greater tumor depth, lymph node metastasis, and advanced TNM stages. To evaluate the contribution of linc-UBC1 to the regulation of CRC, its expression was knocked down in the SW620 cell line, and the subsequent proliferation results showed that reduced expression of linc-UBC1 inhibited cell growth. Furthermore, flow cytometry analyses indicated that decreased expression of linc-UBC1 induced cell apoptosis and cell cycle arrest. Therefore, it is considered that the suppression of cell proliferation may be due to the induction of cell cycle arrest and promotion of apoptosis. Furthermore, the protein levels of Bcl-2, cleaved caspase-3, cleaved caspase-9 indicate that linc-UBC1 inhibits CRC cell apoptosis through the activation of specific caspase cleavage cascades. The decrease in linc-UBC1 expression was also shown to suppress CRC cell migration and invasion ability in vitro. These findings suggest that linc-UBC1 promotes cell proliferation and metastasis in CRC.

With regard to the molecular mechanism of linc-UBC1, it has been confirmed that linc-UBC1 directly interacts with PRC2 and that overexpression promotes cancer progression and poor prognosis of bladder cancer patients.[@b20-ott-10-1017] The PRC2 complex has an important role in carcinogenesis by repressing transcription via histone H3 lysine 27 (H3K27),[@b26-ott-10-1017] and a substantial proportion (24%) of lncRNAs is associated with this complex.[@b22-ott-10-1017],[@b23-ott-10-1017] For example, the lncRNA HOTAIR physically associates with PRC2, which is composed of SUZ12 and EZH2, to promote the progression of various cancer types, including gastrointestinal cancer,[@b27-ott-10-1017] breast cancer,[@b13-ott-10-1017] and hepatocellular carcinoma.[@b28-ott-10-1017] Furthermore, compared with the functional mechanism of linc-UBC1 in bladder cancer,[@b20-ott-10-1017] a similar mechanism may exist in CRC; however, further research is still required to demonstrate the precise molecular mechanisms of linc-UBC1 in CRC.

In the present study, Kaplan--Meier analysis indicated that patients with high levels of linc-UBC1 expression had markedly shorter overall survival time compared to patients with low expression. Multivariate analysis further revealed that linc-UBC1 expression was a significant independent prognostic factor for poor survival of CRC patients. These results indicate that upregulation of linc-UBC1 may have a prominent role in CRC development and progression.

In summary, the present study is the first to report that linc-UBC1 is upregulated in CRC tumor tissues and is associated with tumor size, tumor depth, lymph node metastasis, and TNM stage. Furthermore, the results suggested that linc-UBC1 is an independent predictor of poor overall survival of patients with CRC. Knockdown of linc-UBC1 significantly inhibited proliferation and invasion in vitro. Understanding the critical role of linc-UBC1 in CRC may lead to the development of a novel diagnostic marker for this type of cancer. However, the molecular mechanisms by which linc-UBC1 regulates the CRC cancer migration and invasion require further investigation. As this study is the first to report the biological functions of linc-UBC1 in CRC cancer, further studies in a larger number of samples and investigations of the other possible mechanisms of action are required.
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![Expression of linc-UBC1 and OS curves in 96 patients with CRC.\
**Notes:** (**A**) The expression level of linc-UBC1 in CRC tissues was significantly higher than that in its adjacent noncancerous epithelial tissues (\**P*\<0.001). (**B**) The OS time of the high linc-UBC1 expression group of CRC patients was significantly shorter than that of the low expression group (*P*=0.002).\
**Abbreviations:** linc-UBC1, long non-coding RNA upregulated in bladder cancer 1; OS, overall survival; CRC, colorectal carcinoma.](ott-10-1017Fig1){#f1-ott-10-1017}

![Expression of linc-UBC1 in CRC and normal cells and its role in the regulation of proliferation.\
**Notes:** (**A**) Expression of linc-UBC1 was markedly higher in the majority of CRC cell lines (SW620, HCT116, and HT29) compared with its expression in NCM460 colonic epithelial cells (\**P*\<0.01). The SW620 cell line exhibited the highest expression level. No difference in expression was identified between SW480 and NCM460 cells. (**B**) Following treatment with si-linc-UBC1, linc-UBC1 expression in SW620 cell lines was significantly downregulated compared with that in si-NC-treated cells (\**P*\<0.001). (**C**) The siRNA-mediated silencing of linc-UBC1 significantly inhibited cell proliferation in the SW620 cells (\**P*\<0.05).\
**Abbreviations:** linc-UBC1, long non-coding RNA upregulated in bladder cancer 1; CRC, colorectal carcinoma; siRNA, small interfering RNA; si-linc-UBC1, siRNA targeting linc-UBC1; si-NC, negative control siRNA; OD, optical density.](ott-10-1017Fig2){#f2-ott-10-1017}

![Impact of linc-UBC1 on apoptosis and cell cycle distribution of SW620 cells as analyzed by flow cytometry.\
**Notes:** (**A**) Image of cell apoptosis. (**B**) Image of cell cycle. (**C**) Downregulation of linc-UBC1 induced cell cycle arrest at the G2/M phase (\**P*\<0.01). (**D**) In comparison with si-NC-transfected cells, induction of cell apoptosis was observed in si-linc-UBC1-transfected cells (\**P*\<0.001).\
**Abbreviations:** linc-UBC1, long non-coding RNA upregulated in bladder cancer 1; si-NC, negative control siRNA; si-linc-UBC1, siRNA targeting linc-UBC1; siRNA, small interfering RNA; LR, lower right quadrant; UR, upper right quadrant.](ott-10-1017Fig3){#f3-ott-10-1017}

![Results of the Western blot analysis of the levels of Bcl-2, cleaved caspase-3, cleaved caspase-9, and GAPDH.\
**Notes:** When transfected with si-linc-UBC1, cleaved caspase-3 and cleaved caspase-9 were significantly increased, whereas Bcl-2 was decreased compared with si-NC-transfected cells (*P*\<0.05).\
**Abbreviations:** si-NC, negative control siRNA; si-linc-UBC1, siRNA targeting linc-UBC1; siRNA, small interfering RNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.](ott-10-1017Fig4){#f4-ott-10-1017}

![Impact of linc-UBC1 on the migration and invasion of SW620 cells (crystal violet staining; original magnification, ×200).\
**Notes:** (**A**) When transfected with si-linc-UBC1, fewer SW620 cells migrated through the basement membrane compared with si-NC-transfected cells (\**P*\<0.01). (**B**) When transfected with si-linc-UBC1, fewer SW620 cells invaded through the basement membrane compared with si-NC-transfected cells (\**P*\<0.01).\
**Abbreviations:** linc-UBC1, long non-coding RNA upregulated in bladder cancer 1; si-linc-UBC1, siRNA targeting linc-UBC1; si-NC, negative control siRNA; siRNA, small interfering RNA.](ott-10-1017Fig5){#f5-ott-10-1017}

###### 

Association between linc-UBC1 expression and clinic o-pathological features in 96 patients with colorectal cancer

  Factors                    All cases, n (%)   linc-UBC1 expression   *χ*^2^      *P*-value   
  -------------------------- ------------------ ---------------------- ----------- ----------- -------
  Age at diagnosis (years)                                                                     
   \<60                      49 (51.0)          25 (51.0)              24 (49.0)   0.042       0.838
    ≥60                      47 (49.0)          23 (48.9)              24 (51.1)               
  Gender                                                                                       
   Male                      62 (64.6)          29 (46.8)              33 (53.2)   0.729       0.393
   Female                    34 (35.4)          19 (55.9)              15 (44.1)               
  Tumor location                                                                               
   Colon                     49 (51.0)          23 (46.9)              26 (53.1)   0.375       0.540
   Rectum                    47 (49.0)          25 (53.2)              22 (46.8)               
  Tumor size                                                                                   
   \<5.0 cm                  50 (52.1)          34 (68.0)              16 (32.0)   13.523      0.001
    ≥5.0 cm                  46 (47.9)          14 (30.4)              32 (69.6)               
  Differentiation status                                                                       
   Poor                      35 (36.5)          14 (40.0)              21 (60.0)   2.203       0.138
   Moderate or high          61 (63.5)          34 (55.7)              27 (44.3)               
  Depth of invasion                                                                            
   T1 + T2                   18 (18.8)          13 (72.2)              5 (27.8)    4.376       0.036
   T3 + T4                   78 (81.2)          35 (44.9)              43 (55.1)               
  Lymph node metastasis                                                                        
   N0                        58 (60.4)          35 (60.3)              23 (39.7)   6.672       0.012
   N1 + N2                   38 (39.6)          13 (34.2)              25 (65.8)               
  Distant metastasis                                                                           
   M0                        85 (88.5)          43 (50.6)              42 (49.4)   0.103       0.749
   M1                        11 (11.5)          5 (45.5)               6 (54.5)                
  TNM stage                                                                                    
   I + II                    55 (57.3)          33 (60.0)              22 (40.0)   5.151       0.023
   III + IV                  41 (42.7)          15 (36.6)              26 (63.4)               

**Abbreviation:** linc-UBC1, long non-coding RNA upregulated in bladder cancer 1.

###### 

Multivariate analysis by Cox regression model of factors associated with OS in 96 patients with colorectal cancer

  Factors                                  OS                      
  ---------------------------------------- ------- --------------- -------
  Age at diagnosis (years) (\<60 vs ≥60)   1.093   0.545--2.189    0.803
  Gender (male vs female)                  1.227   0.581--2.591    0.591
  Tumor location (colon vs rectum)         1.446   0.709--2.946    0.310
  Tumor size (\<5.0 vs ≥5.0 cm)            1.871   0.914--3.831    0.086
  Differentiation status (G1 + G2 vs G3)   0.720   0.315--1.646    0.436
  Depth of invasion (T1 + T2 vs T3 + T4)   1.463   0.320--6.696    0.624
  Lymph node metastasis (N0 vs N1 + N2)    0.539   0.158--1.837    0.323
  Distant metastasis (M0 vs M1)            4.016   1.476--10.926   0.006
  TNM stage (I + II vs III + IV)           4.977   1.264--19.605   0.022
  linc-UBC1 expression (high vs low)       2.434   1.093--5.420    0.029

**Abbreviations:** OS, overall survival; linc-UBC1, long non-coding RNA upregulated in bladder cancer 1; CI, confidence interval.
